|View printer-friendly version|
Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies. Portola is evaluating cerdulatinib in an ongoing Phase 1/2 study in patients with relapsed/refractory B-cell malignancies who have failed multiple therapies.
The abstract will be made available at www.AACR.org.
Poster Presentation Details
- Abstract Title (#CT144): Preclinical and clinical studies and modeling and simulation to identify Phase 2 dose for cerdulatinib: a dual SYK/JAK inhibitor for the treatment of B-cell malignancies
- Presenting Author:
Janet M. Leeds, Ph.D., Senior Director, Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals
- Poster Session Title: Phase I Clinical Trials 2
- Presentation Date and Time:
Wednesday, April 20, 7:30 a.m.– 11 a.m. Central Time
Ernest N. Morial Convention Center, Halls G-J, Poster Section 13
Investor Contact: Ana Kapor
Portola Pharmaceuticalsir@portola.com Media Contact: Julie Normart W2O Groupjnormart@w2ogroup.com